Nexalin Technology, Inc.
The Second Xiangya Hospital of Central South University, China, reports affirmative diligent results, including disappearance of each somatic anxiousness symptoms and improved prime of sleep
Treatment effect persisted aft 4 months of follow-up
HOUSTON, TX, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” oregon “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a white paper, titled, “A lawsuit study of Nexalin ADI successful the attraction of somatic symptoms of anxiety,” by the Second Xiangya Hospital of Central South University, China, validating the Company’s tACS instrumentality for the attraction of generalized anxiousness disorder. The achromatic insubstantial details a lawsuit survey of generalized anxiousness upset treated by the assemblage with the Nexalin’s tACS device, successful which the infirmary reported the disappearance of each somatic anxiousness symptoms and improved prime of sleep. The lawsuit survey was overseen by the National Clinical Research Center for Mental Disorders.
The Second Xiangya Hospital of Central South University provided the pursuing statement: “We are pleased to beryllium moving with Nexalin successful bringing this new, effective, safe, and drug-free therapy to our patients with intelligence and neurodegenerative illnesses. We are encouraged by the results of this patient with generalized anxiousness disorder, who received attraction with the 15 milliamp, Nexalin tACS device. The attraction consisted of 2 treatments per time implicit 10 days. The patient, a 42 twelvemonth aged pistillate teacher, suffered repeated carnal discomfort for 23 years, arsenic good arsenic anxiousness and slumber disturbance for 6 months. Her information was diagnosed arsenic systemic somatic symptoms caused by terrible anxiety. We observed the elimination of each somatic symptoms caused by excessive anxiousness and a meaningful betterment successful the prime of sleep. This lawsuit study demonstrated the worth and effectiveness of the Nexalin tACS instrumentality successful treating insomnia, anxiety, and somatic symptoms successful this patient. Moreover, the effect was accelerated and without immoderate broadside effects. Importantly, the attraction effect persisted aft 4 months of follow-up. The findings of this proceedings considerably grow the possibilities for much effectual therapies for patients with generalized anxiousness disorder, portion eliminating the interest associated with the broadside effects of psychiatric drugs. As a result, we look guardant to conducting a larger objective probe study.”
The Second Xiangya Hospital, founded successful 1958, is an affiliate of Central South University, which is the largest Class A infirmary successful Hunan province. According to Fudan University’s ranking of hospitals successful China, the infirmary ranks 13th successful broad spot and 15th successful specializer areas. The infirmary spans 3,500 beds, 40 objective departments, 9 aesculapian laboratories, 127 wards and 4,985 employees.
Nexalin’s tACS exertion is simply a safe, drug-free, non-invasive attraction method, primitively cleared to dainty patients with anxiety, depression, and insomnia. Nexalin has present developed a patented tACS device, which produces a 15 milliamp waveform, designed to penetrate structures heavy successful the mid-brain that are associated with a assortment of intelligence wellness disorders. It is believed that Nexalin’s 15 milliamp waveform volition close irregularities successful the brain’s neurochemical system. Low levels of serotonin (5-hydroxytryptamine, 5-HT) successful the brain’s neurochemical strategy person been associated with assorted intelligence wellness issues. In 2021, Nexalin’s tACS instrumentality was approved by China’s National Medical Products Administration (NMPA) for insomnia and depression.
Mark White, CEO of Nexalin Technology, noted, “We are honored to person our neurostimulation exertion featured successful a achromatic insubstantial by this prestigious assemblage hospital. This achromatic insubstantial reinforces the increasing assemblage of objective grounds supporting the Nexalin 15 milliamp device, which we judge tin person a important interaction connected improving intelligence healthcare outcomes among patients affected with generalized anxiousness disorder. The adoption of our aesculapian instrumentality is poised to heighten intelligence healthcare arsenic aesculapian providers larn that our neurostimulation exertion offers a proven alternate to psychiatric drugs. Nexalin intends to amended the attraction of generalized anxiousness upset and different neurodegenerative diseases. Nexalin’s squad leads the manufacture successful the objective probe of neurostimulation for the attraction of intelligence wellness diseases. We mean to bring our expertise to attraction applications, specified arsenic substance usage upset (SUD), Alzheimer’s and chronic pain. Our ngo is to aggressively grow marketplace consciousness of our breakthrough exertion astir the world.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely and efficaciously assistance combat the ongoing planetary intelligence wellness epidemic. All Nexalin’s products are non-invasive and undetectable to the quality assemblage and supply alleviation to those afflicted with intelligence wellness issues without adverse broadside effects. Nexalin utilizes bioelectronic aesculapian exertion to dainty intelligence wellness issues without the request for drugs oregon psychotherapy. Nexalin believes the 15 milliamp aesculapian instrumentality tin penetrate structures heavy successful the mid-brain that are associated with intelligence wellness disorders. Nexalin believes the deeper penetrating waveform volition make enhanced diligent effect without immoderate adverse broadside effects. The Nexalin tACS instrumentality was precocious approved successful China by the National Medical Products Administration (NMPA) for the attraction of insomnia and depression. In September 2018, Nexalin entered into a bid of agreements with Wider Come Limited (“Wider”), a institution formed nether the laws of the People’s Republic of China. Pursuant to this agreement, Nexalin and Wider person agreed to research the enactment of a associated task entity to beryllium domiciled successful Hong Kong. This caller entity volition behaviour objective probe and instrumentality a concern organisation program for the Nexalin instrumentality successful the Asia Pacific region. Additional accusation astir the Company is disposable at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This property merchandise contains statements that represent "forward-looking statements," including with respect to the Company’s archetypal nationalist offering. Forward-looking statements are taxable to galore conditions, galore of which are beyond the power of the Company, including those acceptable distant successful the Risk Factors conception of the Company's registration connection and prospectus for the offering filed with the SEC. Copies are disposable connected the SEC's website, www.sec.gov. The Company undertakes nary work to update these statements for revisions oregon changes aft the day of this release, but arsenic required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
/cdn.vox-cdn.com/uploads/chorus_asset/file/24020034/226270_iPHONE_14_PHO_akrales_0595.jpg)
English (US)